SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                    FORM 8-K
                                 CURRENT REPORT



     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



         Date of Report (Date of earliest event reported) August 9, 2004
                                                          --------------


                         Progenics Pharmaceuticals, Inc.
              ----------------------------------------------------
             (Exact name of registrant as specified in its charter)



         Delaware                     000-23143                 13-3379479
----------------------------        -------------           --------------------
(State or other jurisdiction         (Commission               (IRS Employer
     of incorporation)               File Number)            Identification No.)



777 Old Saw Mill River Road, Tarrytown, New York              10591
-----------------------------------------------------------------------
(Address of principal executive offices)                    (Zip Code)


Registrant's telephone number, including area code    (914) 789-2800
                                                    ------------------



          ------------------------------------------------------------
         (Former name or former address, if changed since last report.)






Item 7.  Financial Statements and Exhibits

(c)  Exhibits

     Exhibit 99.1            Description
     ------------            -----------
                             Press Release dated August 9, 2004 (filed
                             herewith).


Item 9.  Regulation FD Disclosure.

     On  August  9,  2004,   Progenics   Pharmaceuticals,   Inc.  announced  its
operational  results for the second  quarter  and first half of 2004.  Progenics
Pharmaceuticals  also updated the status of its ongoing  clinical trial studies,
reporting progress in its efforts to bring its developmental  drugs to market. A
copy of the press release is attached as Exhibit 99.1.


     The information  furnished pursuant to Item 9 in this Form 8-K shall not be
deemed to be "filed" for the purposes of Section 18 of the  Securities  Exchange
Act of 1934 or otherwise  subject to the liabilities of that Section,  unless we
specifically  incorporate  it  by  reference  in  a  document  filed  under  the
Securities Act of 1933 or the  Securities  Exchange Act of 1934. We undertake no
duty or  obligation  to  publicly  update or revise  the  information  furnished
pursuant to Item 9 in this Form 8-K.







                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                         PROGENICS PHARMACEUTICALS, INC.


                                         By: /s/ Robert A. McKinney
                                             -----------------------------------
                                                 Robert A. McKinney
                                                 Vice President
                                                 Finance & Operations
                                                 Acting Secretary

Date: August 9, 2004
      --------------